Clinical Trial

Olanzapine for Cancer Related Anorexia-cachexia Syndrome

Unknown Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2024 (before its estimated January 21, 2026 completion). Its status may not reflect the trial's current state.
Summary
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06517199
Lead Sponsor Mahidol University
Conditions Anorexia, Cachexia
Enrollment 138 participants
Start Date 2024-01-22
Primary Completion 2026-01-21 (estimated)
Study Completion 2026-01-21 (estimated)
Updated on ClinicalTrials.gov 2024-07-24